Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma.

Aditi SahaKhushali JhaveriHumaira SarfrazJulio C Chavez

Published in: Expert opinion on biological therapy (2023)

Tisa-cel is a highly effective therapy for heavily pretreated R/R FL with a toxicity profile that is low grade and manageable. Durable remissions (including high-risk patients) are seen in the pivotal ELARA study. Clinicians should consider early referral of R/R FL patients for assessment and discussion.

Keyphrases

end stage renal disease
low grade
ejection fraction
newly diagnosed
chronic kidney disease
primary care
prognostic factors
acute myeloid leukemia
oxidative stress
acute lymphoblastic leukemia
palliative care
multiple myeloma